Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs Ravia Health

Kin Meds
Graded #73

Higher grade

vs+13.700000000000003
Ravia Health
Graded #347

Lower grade

The verdict

Kin Meds takes it — 72.9/100 to 59.2/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +29
74
45
Dose & formulationKin Meds +40
93
53
Clinical oversightRavia Health +13
74
87
Labs & monitoringRavia Health +12
53
65
FulfillmentKin Meds +14
72
58
Contract termsKin Meds +14
55
41
Kin Meds · left barRavia Health · right bar

The numbers

MetricKin MedsRavia Health
WeighScore72.9/10059.2/100
GradeCC
Scorecard rank#73#347
Semaglutide$149/mo (brand Wegovy)Not disclosed
Tirzepatide$149/mo (brand Zepbound)Not disclosed
CoverageCoverage not published1 state
Brand-name accessYesYes
Oral / sublingualYesInjection only
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described
Ravia Health

Graded #347 · C

Strengths

  • Integrative psychiatry model combines GLP-1 weight-loss with mental health and metabolic care under one board-certified NP provider
  • Founded by Dr. Raashida Portier (DNP, PMHNP-BC, FNP-BC); named clinician with dual board certifications in psychiatry and family medicine
  • Membership-supported ongoing care from $49/month provides medication management structure with consistent follow-up
  • Labs and metabolic workup available as part of integrative psychiatry model; lab testing noted in weight-loss program
  • Weight-loss page claims nationwide availability via Lyv Health partnership for eligible patients

Where it loses points

  • GLP-1 medication pricing fully gated — not disclosed until consultation; compounded vs. brand status unclear on public pages
  • Primarily a psychiatric practice — weight loss is a secondary service, not the core offering or brand identity
  • Core services explicitly Florida-only; nationwide weight-loss claim relies on Lyv Health partnership with unverified state coverage
  • No LegitScript certification or third-party accreditation found on public pages
  • Small single-provider practice with no published outcomes data or external reviews available

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard